celiprolol has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Kuraishy, HM | 1 |
| Albuhadily, AK | 1 |
| Al-Gareeb, AI | 1 |
| El-Bouseary, MM | 1 |
| Alexiou, A | 1 |
| Papadakis, M | 1 |
| Batiha, GE | 1 |
1 other study available for celiprolol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Celiprolol and sympatho-immune interface in COVID-19.
Topics: Celiprolol; COVID-19; Humans | 2023 |